A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis

Small, Peter; Houle, Pierre-Alain; Day, James H.; Briscoe, Maureen P.; Gold, Milton; Brodarec, I.; Pong, Anthony Ham; Mandl, Michael; Spénard, Jean; Phillips, Robert A.; Furlan, Monique

doi:10.1016/s0091-6749(97)70160-x

Cited by 26 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings of this non-inferiority trial support the results of previous randomized, parallel-group studies, indicating that triamcinolone acetonide and fluticasone propionate are equally effective for the relief of nasal symptoms in patients with AR [20-23]. In a study by Berger et al [22] in 295 patients with symptomatic SAR, the mean ± SD change in the total nasal symptom score was equivalent between the study medications: –3.15 ± 0.19 with triamcinolone acetonide and –3.17 ± 0.18 with fluticasone propionate after 21 days of treatment.…”

Section: Discussionsupporting

confidence: 83%

“…Similarly, Kaiser et al [21] found a mean change in the total symptom score of –4.84 with triamcinolone acetonide and –4.81 with fluticasone propionate in 150 patients with severe SAR who were treated for 3 weeks. Each of these prior studies administered intranasal triamcinolone acetonide at a daily dose of 220 µg and intranasal fluticasone propionate at a daily dose of 200 µg, which is in accordance with the dosages given in our study [20-23]. …”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Karaulov

Vylegzhanina

Овчинников

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial AR (PAR) in different countries worldwide. Objectives: In order to determine the efficacy of triamcinolone acetonide in the treatment of PAR, the non-inferiority of triamcinolone acetonide to fluticasone propionate was assessed in Russian adults. Methods: In this randomized, double-blind, parallel-group, multicenter, prospective, non-inferiority, phase III clinical trial, a total of 260 patients with persistent PAR were randomized to receive either triamcinolone acetonide or fluticasone propionate nasal sprays for 4 weeks. The efficacy in symptom control was evaluated using the reflective total nasal symptom score (rTNSS) from baseline (day 0) to day 28. Safety was assessed through the reporting of adverse events. Results: The rTNSS mean values decreased from baseline to the end of study treatment (day 28) in both groups: –8.2 ± 3.0 in the triamcinolone acetonide arm versus –8.0 ± 2.8 in the fluticasone propionate arm. The mean difference between the groups (triamcinolone acetonide – fluticasone propionate) for rTNSS change from baseline was –0.2 (95% confidence interval –0.89 to 0.54), with an upper confidence limit of 0.54, which is lower than the non-inferiority margin of 0.8. Triamcinolone acetonide was well tolerated, with no difference in adverse event occurrence compared with fluticasone propionate. Conclusions: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with PAR; both treatments decreased rTNSS values and showed a good safety profile.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 74%

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Karaulov

Vylegzhanina

Овчинников

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…About half (47.9%) of the children did complain of difficulties or unpleasantness with such medication. In contrast, a study conducted on adult subjects showed that the acceptance of triamcinolone acetonide nasal aerosol spray (Nasacort) and fluticasone propionate solution sprays (Flonase) were both well tolerated (26). It therefore appears apparent that children in general might have a lower tolerance than adults for such medication.…”

Section: Discussionmentioning

confidence: 99%

Compliance with topical nasal medication – An evaluation in children with rhinitis

Wong

Soh

Chng

et al. 2010

Pediatric Allergy Immunology

View full text Add to dashboard Cite

It is our impression that children with rhinitis often dislike or struggle with the administration of topical nasal sprays and drops. This study aims to investigate children's acceptance of topical nasal sprays/drops, and to identify patient factors that may affect their acceptance. An interview (by WYZI) questionnaire survey was carried out on parents/guardians of children aged 1-15 with rhinitis, where information on the diagnosis and treatment, patients' use and responses to these medications, and their preferred treatment routes were collected. Two hundred questionnaires were completed, of which 194 were valid for analysis. The mean age of patients was 7.54 yr; male to female ratio was 1:1.6, and Chinese made up the majority (62.4%). About one quarter (24.7%) of children disliked the use of topical nasal sprays/drops sufficiently to affect compliance with the medication. Furthermore, of those who could indicate their preferred route of drug administration (n = 75), 73% indicated a preference for oral medication, while only 11% preferred the nasal route. Topical nasal sprays/drops were more acceptable in older children (7-15 yr) compared to the younger ones (1-6 yr) (OR = 2.383, CI 1.223-4.644). The acceptance of nasal sprays/drops was not associated with gender, ethnic group, concurrent use by other family members, length and amount of usage, and the response to therapy. A substantial proportion of children prescribed topical nasal sprays/drops did not find it acceptable. Age played a significant factor to the acceptance of the use of topical nasal sprays/drops.

show abstract

“…[92][93][94][95] Triamcinolone 220 µg/day and fluticasone 200 µg/day similarly reduced overall symptoms of congestion, rhinorrhea, sneezing, and itching, with no significant difference in symptom scores. 96 Beclomethasone Several intranasal corticosteroids discussed have efficacy equal or superior to beclomethasone for treatment of seasonal and perennial allergic rhinitis. Beclomethasone comes in two formulations, an aerosol and a spray, and is approved for use in adults and children aged 6 years and older.…”

Section: Flunisolidementioning

confidence: 99%

Intranasal Corticosteroids for Allergic Rhinitis

2002

View full text Add to dashboard Cite

Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis. Several intranasal corticosteroids are available: beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate, and triamcinolone acetonide. All are efficacious in treating seasonal allergic rhinitis and as prophylaxis for perennial allergic rhinitis. In general, they relieve nasal congestion and itching, rhinorrhea, and sneezing that occur in the early and late phases of allergic response, with studies showing almost complete prevention of late-phase symptoms. The rationale for topical intranasal corticosteroids in the treatment of allergic rhinitis is that adequate drug concentrations can be achieved at receptor sites in the nasal mucosa. This leads to symptom control and reduces the risk of systemic adverse effects. Adverse reactions usually are limited to the nasal mucosa, such as dryness, burning and stinging, and sneezing, together with headache and epistaxis in 5-10% of patients regardless of formulation or compound. Differences among agents are limited to potency, patient preference, dosing regimens, and delivery, device and vehicle.

show abstract

A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis

Cited by 26 publications

References 4 publications

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Compliance with topical nasal medication – An evaluation in children with rhinitis

Intranasal Corticosteroids for Allergic Rhinitis

Contact Info

Product

Resources

About